Apolipoprotein M predicts pre-β-HDL formation: Studies in type 2 diabetic and nondiabetic subjects

Journal of Internal Medicine

Volumn 266, Issue 3, 2009, Pages 258-267

  Plomgaard, P ^a   Dullaart, R P F ^b   De Vries, R ^b   Groen, A K ^c   Dahlback B ^d   Nielsen, L B ^a,e  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d LUND UNIVERSITY   (Sweden)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Atherosclerosis; Cholesterol metabolism; Human; Insulin resistance; Metabolic syndrome; Obesity

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN M; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PHOSPHOLIPID TRANSFER PROTEIN; PRE BETA HIGH DENSITY LIPOPROTEIN; SULFONYLUREA;

ADULT; ANIMAL CELL; ARTICLE; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST CULTURE; HUMAN; HYPERINSULINEMIA; MAJOR CLINICAL STUDY; MALE; MOUSE; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN ANALYSIS;

AGED; APOLIPOPROTEIN A-I; APOLIPOPROTEINS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CELLS, CULTURED; CHOLESTEROL; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; FEMALE; FIBROBLASTS; HIGH-DENSITY LIPOPROTEINS, PRE-BETA; HUMANS; LINEAR MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PHOSPHOLIPID TRANSFER PROTEINS; STATISTICS, NONPARAMETRIC;

EID: 68949137113     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2009.02095.x     Document Type: Article

References (37)

1. Xu N, Dahlback B. A novel human apolipoprotein (apoM). J Biol Chem 1999 274 : 31286 90.
2. Faber K, Axler O, Dahlback B, Nielsen LB. Characterization of apoM in normal and genetically modified mice. J Lipid Res 2004 45 : 1272 8.
3. Xu N, Nilsson-Ehle P, Ahren B. Correlation of apolipoprotein M with leptin and cholesterol in normal and obese subjects. J Nutr Biochem 2004 15 : 579 82.
4. Christoffersen C, Jauhiainen M, Moser M et al. Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice. J Biol Chem 2008 283 : 1839 47.
5. Christoffersen C, Ahnstrom J, Axler O, Christensen EI, Dahlback B, Nielsen LB. The signal peptide anchors apolipoprotein M in plasma lipoproteins and prevents rapid clearance of apolipoprotein M from plasma. J Biol Chem 2008 283 : 18765 72.
6. Duan J, Dahlback B, Villoutreix BO. Proposed lipocalin fold for apolipoprotein M based on bioinformatics and site-directed mutagenesis. FEBS Lett 2001 499 : 127 32.
7. Ahnstrom J, Faber K, Axler O, Dahlback B. Hydrophobic ligand binding properties of the human lipocalin apolipoprotein M. J Lipid Res 2007 48 : 1754 62.
8. Borggreve SE, de Vries R, Dullaart RPF. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003 33 : 1051 69.
9. Dallinga-Thie GM, Dullaart RPF, van Tol A. Concerted actions of cholesteryl ester transfer protein and phospholipid transfer protein in type 2 diabetes: effects of apolipoproteins. Curr Opin Lipidol 2007 18 : 251 7.
10. Vergeer M, Dallinga-Thie GM, Dullaart RPF, van Tol A. Evaluation of phospholid transfer protein as a therapuetic target. Future Lipidol 2008 3 : 327 35.
11. de Vries R, Dallinga-Thie GM, Smit AJ, Wolffenbuttel BHR, van Tol A, Dullaart RPF. Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus. Diabetologia 2006 49 : 398 404.
12. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006 58 : 342 74.
13. Wolfrum C, Poy MN, Stoffel M. Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med 2005 11 : 418 22.
14. Wolfrum C, Howell J, Ndungo E, Stoffel M. Foxa2 activity increases plasma HDL levels by regulating apolipoprotein M. J Biol Chem 2008 283 : 16940 9.
15. Jauhiainen M, Metso J, Pahlman R, Blomqvist S, van Tol A, Ehnholm C. Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem 1993 268 : 4032 6.
16. Rye KA, Barter PJ. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol 2004 24 : 421 8.
17. Williams KJ, Feig JE, Fisher EA. Cellular and molecular mechanisms for rapid regression of atherosclerosis: from bench top to potentially achievable clinical goal. Curr Opin Lipidol 2007 18 : 443 50.
18. Xu N, Nilsson-Ehle P, Hurtig M, Ahren B. Both leptin and leptin-receptor are essential for apolipoprotein M expression in vivo. Biochem Biophys Res Commun 2004 321 : 916 21.
19. Zhang X, Jiang B, Luo G, Nilsson-Ehle P, Xu N. Hyperglycemia down-regulates apolipoprotein M expression in vivo and in vitro. Biochim Biophys Acta 2007 1771 : 879 82.
20. Richter S, Shih DQ, Pearson ER et al. Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor-1alpha: haploinsufficiency is associated with reduced serum apolipoprotein M levels. Diabetes 2003 52 : 2989 95.
21. Skupien J, Kepka G, Gorczynska-Kosiorz S et al. Evaluation of Apolipoprotein M serum concentration as a biomarker of HNF-1alpha MODY. Rev Diabet Stud 2007 4 : 231 5.
22. Axler O, Ahnstrom J, Dahlback B. An ELISA for apolipoprotein M reveals a strong correlation to total cholesterol in human plasma. J Lipid Res 2007 48 : 1772 80.
23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 : 412 9.
24. Speijer H, Groener JE, van Ramshorst E, van Tol A. Different locations of cholesteryl ester transfer protein and phospholipid transfer protein activities in plasma. Atherosclerosis 1991 90 : 159 68.
25. van Haperen R, van Tol A, Vermeulen P et al. Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arterioscler Thromb Vasc Biol 2000 20 : 1082 8.
26. de Vries R, Groen AK, Perton FG et al. Increased cholesterol efflux from cultured fibroblasts to plasma from hypertriglyceridemic type 2 diabetic patients: roles of pre beta-HDL, phospholipid transfer protein and cholesterol esterification. Atherosclerosis 2008 196 : 733 41.
27. de Vries R, Kerstens MN, Sluiter WJ, Groen AK, van Tol A, Dullaart RPF. Cellular cholesterol efflux to plasma from moderately hypercholesterolaemic type 1 diabetic patients is enhanced, and is unaffected by simvastatin treatment. Diabetologia 2005 48 : 1105 13.
28. Hovingh GK, van Wijland MJ, Brownlie A et al. The role of the ABCA1 transporter and cholesterol efflux in familial hypoalphalipoproteinemia. J Lipid Res 2003 44 : 1251 5.
29. Yancey PG, Bortnick AE, Kellner-Weibel G, de la Llera-Moya M, Phillips MC, Rothblat GH. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2003 23 : 712 9.
30. Adorni MP, Zimetti F, Billheimer JT et al. The roles of different pathways in the release of cholesterol from macrophages. J Lipid Res 2007 48 : 2453 62.
31. Duong M, Collins HL, Jin W, Zanotti I, Favari E, Rothblat GH. Relative contributions of ABCA1 and SR-BI to cholesterol efflux to serum from fibroblasts and macrophages. Arterioscler Thromb Vasc Biol 2006 26 : 541 7.
32. Christoffersen C, Nielsen LB, Axler O, Andersson A, Johnsen AH, Dahlback B. Isolation and characterization of human apolipoprotein M-containing lipoproteins. J Lipid Res 2006 47 : 1833 43.
33. Gelissen IC, Harris M, Rye KA et al. ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. Arterioscler Thromb Vasc Biol 2006 26 : 534 40.
34. Yancey PG, Yu H, Linton MF, Fazio S. A pathway-dependent on apoE, ApoAI, and ABCA1 determines formation of buoyant high-density lipoprotein by macrophage foam cells. Arterioscler Thromb Vasc Biol 2007 27 : 1123 31.
35. Gelissen IC, Hochgrebe T, Wilson MR et al. Apolipoprotein J (clusterin) induces cholesterol export from macrophage-foam cells: a potential anti-atherogenic function? Biochem J 1998 331 : 231 7.
36. Ahnstrom J, Axler O, Jauhiainen M et al. Levels of apolipoprotein M are not associated with the risk of coronary heart disease in two independent case-control studies. J Lipid Res 2008 49 : 1912 7 Epub ahead of print).
37. Venteclef N, Haroniti A, Tousaint JJ, Talianidis I, Delerive P. Regulation of anti-atherogenic apolipoprotein M gene expression by the orphan nuclear receptor LRH-1. J Biol Chem 2008 283 : 3694 701.